SRA737 valuation - according to AI13 Aug 2025 15:51
Good afternoon PCS1954, re valuations…
Q: Assuming SRa737 is licenced by Sareum holdings to a mid sized pharma company what is the likely size of the deal?
Short answer first, then the reasoning and citations.
Likely deal-size (three scenarios)
• Conservative / risk-heavy: Upfront $1–5M, development + regulatory + commercial milestones $20–80M total, royalties ~8–12% on net sales.
• Base-case (most likely for a “mid-sized” pharma if there are decent Phase I/II data): Upfront $10–30M, milestones $150–400M, royalties ~12–18%.
• Optimistic / competitive auction: Upfront $30–80M, milestones $400M–$1B+, royalties 15–25% (tiered).
Why those ranges?
1. Clinical stage & risk — SRA737 is a CHK1 inhibitor that has been investigated in Phase I/II trials (so it’s not preclinical but not late-stage). Assets at this stage attract mid-size pharma interest but carry significant clinical risk, which compresses upfronts compared with Phase III assets.  
2. Market trends / benchmarks — Recent industry benchmarking shows Phase II licensing upfront medians in the tens of millions (reports vary; some show medians around ~$28M while other market surveys put typical upfronts and milestone pools substantially higher for sought-after assets). These industry medians are why the base case has a mid-double-digit upfront and large milestone pools.  
3. Deal structure conventions — Typical structures for oncology small molecules: modest-to-substantial upfront, many development/regulatory milestones (often hundreds of millions in aggregate), and tiered royalties in the low-to-mid teens (sometimes higher if the partner takes full commercialisation). LES and industry surveys show royalty/milestone mixes are common and vary by novelty, indication breadth, and commercial potential.  
4. Sareum’s recent history with SRA737 — Sareum previously had SRA737 licensed with relatively small near-term receipts reported (an upfront in the US$100k range to Sareum under certain arrangements), illustrating that if the asset’s data or negotiating leverage is limited then real near-term cash to the originator can be small. That historical point anchors the lower end of the possible range. (A new deal after refreshed data or with broader rights would be priced very differently.)  
Key deal drivers (what would push a deal toward the optimistic vs conservative end)
• Strength and recency of clinical data (monotherapy signal, combo activity, biomarker-defined responders).
• Clear biomarker strategy and ability to select responsive patients (raises value).
• Breadth of rights (global vs regional; commercial vs co-development).
• Ability / willingness of licensee to run combination trials (costly; if licensee takes on full cost, upfronts may be higher).
• Competitive interest / auction dynamics — multiple bidders can push upfronts and milestones up dramatically.
• Existing royal
Sign In
Follow the stocks
